EX-99.2 3 a2019q3exhibit992.htm EXHIBIT 99.2 Exhibit

Exhibit 99.2


Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
THIRD QUARTER
 
 
 
 
 
Percent Change
 
2019
 
2018
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
geographic area
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S.
 $ 10,791
 
  10,664
 
   1.2

%
            1.2
 
—

 
 
 
 
 
 
 
 
 
 
Europe
      4,461
 
    4,416
 
1.0

 
            5.2
 
(4.2
)
Western Hemisphere excluding U.S.
      1,488
 
    1,550
 
(4.0
)
 
            1.0
 
(5.0
)
Asia-Pacific, Africa
      3,989
 
    3,718
 
   7.3

 
            7.5
 
(0.2
)
International
      9,938
 
    9,684
 
   2.6

 
            5.4
 
(2.8
)
 
 
 
 
 
  
 
  
 
 
Worldwide
 $ 20,729
 
  20,348
 
   1.9

%
            3.2
 
(1.3
)
 
 
 
  
 
  
 
  
 
  
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.







Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
NINE MONTHS
 
 
 
 
 
Percent Change
 
2019
 
2018
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
geographic area
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S.
 $ 31,323
 
  31,255
 
   0.2

%
            0.2
 
—

 
 
 
 
 
 
 
 
 
 
Europe
    13,803
 
  14,023
 
(1.6
)
 
            4.8
 
(6.4
)
Western Hemisphere excluding U.S.
      4,446
 
    4,657
 
(4.5
)
 
            4.6
 
(9.1
)
Asia-Pacific, Africa
    11,740
 
  11,252
 
   4.3

 
            7.2
 
(2.9
)
International
    29,989
 
  29,932
 
   0.2

 
            5.7
 
(5.5
)
 
 
 
  
 
  
 
  
 
 
Worldwide
 $ 61,312
 
  61,187
 
   0.2

%
            2.9
 
(2.7
)
 
 
 
  
 
  
 
  
 
  
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
THIRD QUARTER
 
 
 
 
 
Percent Change
 
2019
 
2018
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
segment of business
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consumer
 
 
 
 
 
 
 
 
 
    U.S.
 $ 1,394
 
    1,370
 
   1.7

%
            1.7

 
—

    International
      2,075
 
    2,045
 
   1.4

 
            4.3

 
(2.9
)
 
      3,469
   
    3,415
 
   1.6

 
            3.3

 
(1.7
)
 
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
    U.S.
      6,340
 
    6,097
 
   4.0

 
            4.0

 
—

    International
      4,537
 
    4,249
 
   6.8

 
          10.0

 
(3.2
)
 
    10,877
   
  10,346
 
   5.1

 
            6.4

 
(1.3
)
 
 
 
 
 
 
 
 
 
 
Medical Devices
 
 
 
 
 
 
 
 
 
    U.S.
      3,057
   
    3,197
 
(4.4
)
 
(4.4
)
 
—

    International
      3,326
 
    3,390
 
(1.9
)
 
            0.3

 
(2.2
)
 
      6,383
   
    6,587
 
(3.1
)
 
(2.0
)
 
(1.1
)
 
 
 
 
 
 
 
 
 
 
U.S.
    10,791
 
  10,664
 
   1.2

 
            1.2

 
—

International
      9,938
 
    9,684
 
   2.6

 
            5.4

 
(2.8
)
Worldwide
 $ 20,729
 
  20,348
 
   1.9

%
            3.2

 
(1.3
)
 
   
 
 
 
 
 
 
 
 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.































Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
NINE MONTHS
 
 
 
 
 
Percent Change
 
2019
 
2018
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
segment of business
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consumer
 
 
 
 
 
 
 
 
 
    U.S.
 $ 4,369
 
    4,282
 
   2.0

%
            2.0
 
—

    International
      5,962
 
    6,035
 
(1.2
)
 
            4.3
 
(5.5
)
 
    10,331
   
  10,317
 
   0.1

 
            3.4
 
(3.3
)
 
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
    U.S.
    17,705
 
  17,350
 
   2.0

 
            2.0
 
—

    International
    13,945
 
  13,194
 
   5.7

 
          11.7
 
(6.0
)
 
    31,650
   
  30,544
 
   3.6

 
            6.2
 
(2.6
)
 
 
 
 
 
 
 
 
 
 
Medical Devices
 
 
 
 
 
 
 
 
 
    U.S.
      9,249
   
    9,623
 
(3.9
)
 
          (3.9)
 
—

    International
    10,082
 
  10,703
 
(5.8
)
 
          (1.0)
 
(4.8
)
 
    19,331
   
  20,326
 
(4.9
)
 
          (2.4)
 
(2.5
)
 
 
 
 
 
 
 
 
 
 
U.S.
    31,323
 
  31,255
 
   0.2

 
            0.2
 
—

International
    29,989
 
  29,932
 
   0.2

 
            5.7
 
(5.5
)
Worldwide
 $ 61,312
 
  61,187
 
   0.2

%
            2.9
 
(2.7
)
 
   
 
 
 
 
 
 
 
 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.


Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Condensed Consolidated Statement of Earnings
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; in Millions Except Per Share Figures)
THIRD QUARTER
 
 
 
 
 
 
 
 
 
 
 
2019
 
2018
 
Percent
 
 
 
Percent
 
 
 
Percent
 
Increase
 
Amount
 
to Sales
 
Amount
 
to Sales
 
(Decrease)
Sales to customers
 $ 20,729

 
     100.0

 
 $ 20,348
 
     100.0
 
1.9
Cost of products sold
      6,867

 
       33.1

 
      6,589
 
       32.4
 
4.2
Gross Profit
    13,862

 
       66.9

 
    13,759
 
       67.6
 
0.7
Selling, marketing and administrative expenses
      5,374

 
       26.0

 
      5,543
 
       27.3
 
(3.0)
Research and development expense
      2,599

 
       12.5

 
      2,508
 
       12.3
 
3.6
In-process research and development
—

 
—

 
      1,126
 
         5.6
 
 
Interest (income) expense, net
         (41)

 
       (0.2)

 
           68
 
         0.3
 
 
Other (income) expense, net
         214

 
         1.0

 
             3
 
         0.0
 
 
Restructuring
           69

 
         0.4

 
           88
 
         0.4
 
 
Earnings before provision for taxes on income
      5,647

 
       27.2

 
      4,423
 
       21.7
 
27.7
Provision for taxes on income
         814

 
         3.9

 
         489
 
         2.4
 
66.5
Net earnings
 $ 4,833

 
       23.3

 
 $ 3,934
 
       19.3
 
22.9
 
 
 
 
 
 
 
 
 
 
Net earnings per share (Diluted)
 $ 1.81

 
 
 
 $ 1.44
 
 
 
25.7
 
 
 
 
 
 
 
 
 
 
Average shares outstanding (Diluted)
2,669.9

 
 
 
2,727.6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
14.4

%
 
 
11.1
%
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted earnings before provision for taxes and net earnings (1) (A)
 
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income
 $ 7,116

 
34.3

 
 $ 6,780
 
33.3
 
5.0
Net earnings
 $ 5,672

 
27.4

 
 $ 5,590
 
27.5
 
1.5
Net earnings per share (Diluted)
 $ 2.12

 
 
 
 $ 2.05
 
 
 
3.4
Effective tax rate
20.3

%
 
 
17.6
%
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) See Reconciliation of Non-GAAP Financial Measures.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.




Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Condensed Consolidated Statement of Earnings
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; in Millions Except Per Share Figures)
NINE MONTHS
 
 
 
 
 
 
 
 
 
 
 
2019
 
2018
 
Percent
 
 
 
Percent
 
 
 
Percent
 
Increase
 
Amount
 
to Sales
 
Amount
 
to Sales
 
(Decrease)
Sales to customers
 $ 61,312
 
     100.0
 
 $ 61,187
 
     100.0
 
0.2
Cost of products sold
    20,422
 
       33.3
 
    20,130
 
       32.9
 
1.5
Gross Profit
    40,890
 
       66.7
 
    41,057
 
       67.1
 
(0.4)
Selling, marketing and administrative expenses
    16,139
 
       26.3
 
    16,549
 
       27.1
 
(2.5)
Research and development expense
      8,123
 
       13.3
 
      7,551
 
       12.3
 
7.6
In-process research and development
         890
 
         1.4
 
      1,126
 
         1.8
 
 
Interest (income) expense, net
         (43)
 
       (0.1)
 
         340
 
         0.6
 
 
Other (income) expense, net
    (1,491)
 
       (2.4)
 
         427
 
         0.7
 
 
Restructuring
         162
 
         0.3
 
         187
 
         0.3
 
 
Earnings before provision for taxes on income
    17,110
 
       27.9
 
    14,877
 
       24.3
 
15.0
Provision for taxes on income
      2,921
 
         4.8
 
      2,622
 
         4.3
 
11.4
Net earnings
 $ 14,189
 
       23.1
 
 $ 12,255
 
       20.0
 
15.8
 
 
 
 
 
 
 
 
 
 
Net earnings per share (Diluted)
 $ 5.28
 
 
 
 $ 4.49
 
 
 
17.6
 
 
 
 
 
 
 
 
 
 
Average shares outstanding (Diluted)
2,688.1
 
 
 
2,729.6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
17.1
%
 
 
17.6
%
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted earnings before provision for taxes and net earnings (1) (A)
 
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income
 $ 22,597
 
36.9
 
 $ 20,652
 
33.8
 
9.4
Net earnings
 $ 18,283
 
29.8
 
 $ 16,943
 
27.7
 
7.9
Net earnings per share (Diluted)
 $ 6.80
 
 
 
 $ 6.21
 
 
 
9.5
Effective tax rate
19.1
%
 
 
18.0
%
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) See Reconciliation of Non-GAAP Financial Measures.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.
















Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measures
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Third Quarter
 
% Incr. /
 
(Dollars in Millions Except Per Share Data)
2019
 
2018
 
(Decr.)
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income - as reported
 $ 5,647

 
  4,423

 
      27.7
%
Intangible asset amortization expense
    1,138

 
  1,085

 
 
 
In-process research and development
—

 
  1,126

 
 
 
Litigation expense, net
—

 
—

 
 
 
Restructuring/Other (1)
       128

 
     190

 
 
 
Actelion acquisition related cost
         33

 
       40

 
 
 
Auris Health acquisition related cost
         65

 
—

 
 
 
AMO acquisition related cost
           9

 
       36

 
 
 
Unrealized loss/(gain) on securities
         89

 
         9

 
 
 
Contingent liability reversal
—

 
   (184)

 
 
 
Diabetes asset impairment
—

 
—

 
 
 
Other
           7

 
       55

 
 
 
Earnings before provision for taxes on income - as adjusted
 $ 7,116

 
  6,780

 
        5.0
 %
 
 
 
 
 
 
 
Net Earnings - as reported
 $ 4,833

 
  3,934

 
      22.9
%
Intangible asset amortization expense
    1,011

 
     968

 
 
 
In-process research and development
—

 
     859

 
 
 
Litigation expense, net
—

   
—

   
 
 
Restructuring/Other
       106

 
     162

 
 
 
Actelion acquisition related cost
         30

 
       37

 
 
 
Auris Health acquisition related cost
         51

 
—

 
 
 
AMO acquisition related cost
           7

 
       29

 
 
 
Unrealized loss/(gain) on securities
         71

 
         8

 
 
 
Contingent liability reversal
—

 
   (184)

 
 
 
Diabetes asset impairment
—

 
—

 
 
 
Impact of tax legislation (2)
     (391)

 
   (265)

 
 
 
Other
       (46)

 
       42

 
 
 
Net Earnings - as adjusted
 $ 5,672

 
  5,590

 
        1.5
 %
 
 
 
 
 
 
 
Diluted Net Earnings per share - as reported
 $ 1.81

 
    1.44

 
      25.7
%
Intangible asset amortization expense
      0.38

 
    0.35

 
 
 
In-process research and development
—

 
    0.32

 
 
 
Litigation expense, net
—

 
—

 
 
 
Restructuring/Other
      0.04

 
    0.06

 
 
 
Actelion acquisition related cost
      0.01

 
    0.02

 
 
 
Auris Health acquisition related cost
      0.02

 
—

 
 
 
AMO acquisition related cost
—

 
    0.01

 
 
 
Unrealized loss/(gain) on securities
      0.03

 
—

 
 
 
Contingent liability reversal
—

 
  (0.07)

 
 
 
Diabetes asset impairment
—

 
—

 
 
 
Impact of tax legislation
    (0.15)

 
  (0.10)

 
 
 
Other
    (0.02)

 
    0.02

 
 
 
Diluted Net Earnings per share - as adjusted
 $ 2.12

 
    2.05

 
        3.4
 %
 
 
 
 
 
 
 
Operational Diluted Net Earnings per share - as adjusted
 
 
 
 
 
 
at 2017 foreign currency exchange rates
 
 
    2.08

 
 
 
 
 
 
 
 
 
 
Impact of currency at 2018 foreign currency exchange rates
      0.05

 
  (0.03)

 
 
 
 
 
 
 
 
 
 
Operational Diluted Net Earnings per share - as adjusted
 
 
 
 
 
 
at 2018 foreign currency exchange rates
 $ 2.17

 
    2.05

 
        5.9
 %
 
 
 
 
 
 
 
(1) Includes $20M recorded in cost of products sold and $39M recorded in other (income) expense for the third quarter 2019. Includes $23M recorded in cost of products sold and $79M recorded in other (income) expense for the third quarter 2018.
 
 
 
 
 
 
 
(2) Includes foreign currency translation

 
 
 
 
 
 




Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measures
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nine Months YTD
 
% Incr. /
 
(Dollars in Millions Except Per Share Data)
2019
 
2018
 
(Decr.)
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income - as reported
 $ 17,110

 
  14,877

 
      15.0
%
Intangible asset amortization expense
      3,386

 
    3,284

 
 
 
In-process research and development
         890

 
    1,126

 
 
 
Litigation expense, net
         832

 
       703

 
 
 
Restructuring/Other (1)
         360

 
       473

 
 
 
Actelion acquisition related cost
         123

 
       200

 
 
 
Auris Health acquisition related cost
           56

 
—

 
 
 
AMO acquisition related cost
           50

 
         82

 
 
 
Unrealized loss/(gain) on securities
       (217)

 
         (3)

 
 
 
Contingent liability reversal
—

 
     (184)

 
 
 
Diabetes asset impairment
—

 
           4

 
 
 
Other
             7

 
         90

 
 
 
Earnings before provision for taxes on income - as adjusted
 $ 22,597

 
  20,652

 
        9.4
 %
 
 
 
 
 
 
 
Net Earnings - as reported
 $ 14,189

 
  12,255

 
      15.8
%
Intangible asset amortization expense
      2,836

 
    2,931

 
 
 
In-process research and development
         703

 
       859

 
 
 
Litigation expense, net
         684

 
       609

 
 
 
Restructuring/Other
         297

 
       395

 
 
 
Actelion acquisition related cost
         114

 
       193

 
 
 
Auris Health acquisition related cost
           44

 
—

 
 
 
AMO acquisition related cost
           40

 
         68

 
 
 
Unrealized loss/(gain) on securities
       (171)

 
         (2)

 
 
 
Contingent liability reversal
—

 
     (184)

 
 
 
Diabetes asset impairment
—

 
           3

 
 
 
Impact of tax legislation (2)
       (391)

 
     (253)

 
 
 
Other
         (62)

 
         69

 
 
 
Net Earnings - as adjusted
 $ 18,283

 
  16,943

 
        7.9
 %
 
 
 
 
 
 
 
Diluted Net Earnings per share - as reported
 $ 5.28

 
      4.49

 
      17.6
%
Intangible asset amortization expense
        1.06

 
      1.07

 
 
 
In-process research and development
        0.26

 
      0.32

 
 
 
Litigation expense, net
        0.25

 
      0.22

 
 
 
Restructuring/Other
        0.11

 
      0.15

 
 
 
Actelion acquisition related cost
        0.04

 
      0.07

 
 
 
Auris Health acquisition related cost
        0.02

 
—

 
 
 
AMO acquisition related cost
        0.01

 
      0.02

 
 
 
Unrealized loss/(gain) on securities
      (0.06)

 
—

 
 
 
Contingent liability reversal
—

 
    (0.07)

 
 
 
Diabetes asset impairment
—

 
—

 
 
 
Impact of tax legislation
      (0.15)

 
    (0.09)

 
 
 
Other
      (0.02)

 
      0.03

 
 
 
Diluted Net Earnings per share - as adjusted
 $ 6.80

 
      6.21

 
        9.5
 %
 
 
 
 
 
 
 
Operational Diluted Net Earnings per share - as adjusted
 
 
 
 
 
 
at 2017 foreign currency exchange rates
 
 
      6.04

 
 
 
 
 
 
 
 
 
 
Impact of currency at 2018 foreign currency exchange rates
        0.18

 
      0.17

 
 
 
 
 
 
 
 
 
 
Operational Diluted Net Earnings per share - as adjusted
 
 
 
 
 
 
at 2018 foreign currency exchange rates
 $ 6.98

 
      6.21

 
      12.4
 %
 
 
 
 
 
 
 
(1) Includes $81M recorded in cost of products sold and $117M recorded in other (income) expense for nine months 2019 YTD. Includes $73M recorded in cost of products sold and $213M recorded in other (income) expense for nine months 2018 YTD.
 
 
 
 
 
 
 
(2) Includes foreign currency translation
 
 
 
 
 
 



Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted Operational Sales Growth (A)
 THIRD QUARTER 2019 ACTUAL vs. 2018 ACTUAL
 
 
 
 
 
 
 
 
 
 Segments
 
 
 
 
 
 
 
 
 
 
 
 Consumer
 
 Pharmaceutical
 
 Medical Devices
 
 Total
 WW As Reported
 
1.6%
 
5.1%
 
(3.1)%
 
1.9%
 U.S.
 
1.7%
 
4.0%
 
(4.4)%
 
1.2%
 International
 
1.4%
 
6.8%
 
(1.9)%
 
2.6%
 
 
 
 
 
 
 
 
 
 WW Currency
 
(1.7)
 
(1.3)
 
(1.1)
 
(1.3)
 U.S.
 
—
 
—
 
—
 
—
 International
 
(2.9)
 
(3.2)
 
(2.2)
 
(2.8)
 
 
 
 
 
 
 
 
 
 WW Operational
 
3.3%
 
6.4%
 
(2.0)%
 
3.2%
 U.S.
 
1.7%
 
4.0%
 
(4.4)%
 
1.2%
 International
 
4.3%
 
10.0%
 
0.3%
 
5.4%
 
 
 
 
 
 
 
 
 
OTC
 
 
 
 
 
 
 
 
Zarbees
 
(0.4)
 
 
 
 
 
(0.1)
 U.S.
 
(1.0)
 
 
 
 
 
(0.1)
 International
 
0.0
 
 
 
 
 
0.0
 
 
 
 
 
 
 
 
 
Diabetes Care
 
 
 
 
 
 
 
 
LifeScan
 
 
 
 
 
5.1
 
1.6
 U.S.
 
 
 
 
 
4.0
 
1.2
 International
 
 
 
 
 
6.1
 
2.1
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
RoC
 
0.5
 
 
 
 
 
0.1
 U.S.
 
1.1
 
 
 
 
 
0.1
 International
 
0.1
 
 
 
 
 
0.0
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
Dr. Ci Labo - Japan
 
(2.3)
 
 
 
 
 
(0.4)
 U.S.
 
0.0
 
 
 
 
 
0.0
 International
 
(3.9)
 
 
 
 
 
(0.8)
 
 
 
 
 
 
 
 
 
Specialty Surgery
 
 
 
 
 
 
 
 
Advanced Sterilization Products
 
 
 
 
 
2.1
 
0.7
 U.S.
 
 
 
 
 
2.9
 
0.9
 International
 
 
 
 
 
1.4
 
0.5
 
 
 
 
 
 
 
 
 
Baby Care
 
 
 
 
 
 
 
 
Baby Center
 
0.2
 
 
 
 
 
0.0
 U.S.
 
0.5
 
 
 
 
 
0.1
 International
 
0.0
 
 
 
 
 
0.0
 
 
 
 
 
 
 
 
 
All Other Acquisitions and Divestitures
 
0.0
 
0.0
 
0.0
 
0.0
 U.S.
 
0.0
 
0.0
 
(0.1)
 
0.0
 International
 
0.1
 
0.0
 
0.1
 
0.1
 
 
 
 
 
 
 
 
 
WW Adjusted Operational
 
1.3%
 
6.4%
 
5.3%
 
5.2%
 U.S.
 
2.4%
 
4.0%
 
2.5%
 
3.4%
 International
 
0.6%
 
10.0%
 
8.0%
 
7.3%
 
 
 
 
 
 
 
 
 
Note: Percentages are based on actual, non-rounded figures and may not sum
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.





Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted Operational Sales Growth (A)
 NINE MONTHS 2019 ACTUAL vs. 2018 ACTUAL
 
 
 
 
 
 
 
 
 
 Segments
 
 
 
 
 
 
 
 
 
 
 
 Consumer
 
 Pharmaceutical
 
 Medical Devices
 
 Total
 WW As Reported
 
0.1%
 
3.6%
 
(4.9)%
 
0.2%
 U.S.
 
2.0%
 
2.0%
 
(3.9)%
 
0.2%
 International
 
(1.2)%
 
5.7%
 
(5.8)%
 
0.2%
 
 
 
 
 
 
 
 
 
 WW Currency
 
(3.3)
 
(2.6)
 
(2.5)
 
(2.7)
 U.S.
 
—
 
—
 
—
 
—
 International
 
(5.5)
 
(6.0)
 
(4.8)
 
(5.5)
 
 
 
 
 
 
 
 
 
 WW Operational
 
3.4%
 
6.2%
 
(2.4)%
 
2.9%
 U.S.
 
2.0%
 
2.0%
 
(3.9)%
 
0.2%
 International
 
4.3%
 
11.7%
 
(1.0)%
 
5.7%
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
Nizoral
 
0.3
 
 
 
 
 
0.1
 U.S.
 
0.2
 
 
 
 
 
0.0
 International
 
0.4
 
 
 
 
 
0.1
 
 
 
 
 
 
 
 
 
OTC
 
 
 
 
 
 
 
 
Zarbees
 
(0.6)
 
 
 
 
 
(0.1)
 U.S.
 
(1.5)
 
 
 
 
 
(0.2)
 International
 
0.0
 
 
 
 
 
0.0
 
 
 
 
 
 
 
 
 
Diabetes Care
 
 
 
 
 
 
 
 
LifeScan
 
 
 
 
 
5.1
 
1.7
 U.S.
 
 
 
 
 
4.0
 
1.2
 International
 
 
 
 
 
6.1
 
2.2
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
RoC
 
0.7
 
 
 
 
 
0.1
 U.S.
 
1.3
 
 
 
 
 
0.2
 International
 
0.2
 
 
 
 
 
0.0
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
Dr. Ci Labo - Japan
 
(2.5)
 
 
 
 
 
(0.4)
 U.S.
 
0.0
 
 
 
 
 
0.0
 International
 
(4.2)
 
 
 
 
 
(0.9)
 
 
 
 
 
 
 
 
 
Specialty Surgery
 
 
 
 
 
 
 
 
Advanced Sterilization Products
 
 
 
 
 
1.4
 
0.5
 U.S.
 
 
 
 
 
1.9
 
0.6
 International
 
 
 
 
 
0.8
 
0.3
 
 
 
 
 
 
 
 
 
Baby Care
 
 
 
 
 
 
 
 
Baby Center
 
0.1
 
 
 
 
 
0.0
 U.S.
 
0.2
 
 
 
 
 
0.0
 International
 
0.0
 
 
 
 
 
0.0
 
 
 
 
 
 
 
 
 
All Other Acquisitions and Divestitures
 
0.1
 
0.0
 
0.1
 
0.1
 U.S.
 
0.0
 
0.0
 
0.1
 
0.0
 International
 
0.2
 
0.0
 
0.1
 
0.1
 
 
 
 
 
 
 
 
 
WW Adjusted Operational
 
1.4%
 
6.2%
 
4.3%
 
4.8%
 U.S.
 
2.2%
 
2.0%
 
2.2%
 
2.1%
 International
 
0.8%
 
11.7%
 
6.1%
 
7.6%
 
 
 
 
 
 
 
 
 
Note: Percentages are based on actual, non-rounded figures and may not sum
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.





Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
THIRD QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

CONSUMER SEGMENT (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BABY CARE
 
 
 
 
 
 
 
 
 
US
 
$
91

 
120

 
(24.1
)%
(24.1
)%
—
 %
Intl
 
 
326

 
352

 
(7.3
)
(4.9
)
(2.4
)
WW
 
 
417

 
472

 
(11.6
)
(9.8
)
(1.8
)
 
 
 
 
 
 
 
 
 
 
BEAUTY
 
 
 
 
 
 
 
 
 
US
 
 
559

 
543

 
2.9

2.9

—

Intl
 
 
592

 
535

 
10.8

13.5

(2.7
)
WW
 
 
1,151

 
1,078

 
6.8

8.1

(1.3
)
 
 
 
 
 
 
 
 
 
 
ORAL CARE
 
 
 
 
 
 
 
 
 
US
 
 
156

 
158

 
(1.1
)
(1.1
)
—

Intl
 
 
223

 
226

 
(1.6
)
1.1

(2.7
)
WW
 
 
379

 
384

 
(1.4
)
0.2

(1.6
)
 
 
 
 
 
 
 
 
 
 
OTC
 
 
 
 
 
 
 
 
 
US
 
 
477

 
440

 
8.4

8.4

—

Intl
 
 
621

 
608

 
2.2

5.2

(3.0
)
WW
 
 
1,098

 
1,048

 
4.8

6.5

(1.7
)
 
 
 
 
 
 
 
 
 
 
WOMEN'S HEALTH
 
 
 
 
 
 
 
 
 
US
 
 
3

 
3

 
(4.0
)
(4.0
)
—

Intl
 
 
252

 
266

 
(5.4
)
(1.3
)
(4.1
)
WW
 
 
255

 
269

 
(5.3
)
(1.3
)
(4.0
)
 
 
 
 
 
 
 
 
 
 
WOUND CARE / OTHER
 
 
 
 
 
 
 
 
 
US
 
 
109

 
106

 
1.9

1.9

—

Intl
 
 
59

 
58

 
3.3

4.9

(1.6
)
WW
 
 
168

 
164

 
2.4

3.0

(0.6
)
 
 
 
 
 
 
 
 
 
 
TOTAL CONSUMER
 
 
 
 
 
 
 
 
 
US
 
 
1,394

 
1,370

 
1.7

1.7

—

Intl
 
 
2,075

 
2,045

 
1.4

4.3

(2.9
)
WW
 
$
3,469

 
3,415

 
1.6
 %
3.3
 %
(1.7
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 





Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
THIRD QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (4)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMMUNOLOGY
 
 
 
 
 
 
 
 
 
US
 
$
2,582

 
2,400

 
7.6
 %
7.6
 %
—
 %
Intl
 
 
1,129

 
998

 
13.2

16.8

(3.6
)
WW
 
 
3,711

 
3,398

 
9.3

10.3

(1.0
)
     REMICADE
 
 
 
 
 
 
 
 
 
     US
 
 
749

 
987
 
(24.1
)
(24.1
)
—

     US Exports (3)
 
 
88

 
100

 
(12.0
)
(12.0
)
—

     Intl
 
 
299

 
292

 
2.5

6.1

(3.6
)
     WW
 
 
1,136

 
1,379

 
(17.6
)
(16.9
)
(0.7
)
     SIMPONI / SIMPONI ARIA
 
 
 
 
 
 
 
 
 
     US
 
 
313

 
281

 
11.6

11.6

—

     Intl
 
 
273

 
255

 
7.3

9.9

(2.6
)
     WW
 
 
586

 
536

 
9.6

10.8

(1.2
)
     STELARA
 
 
 
 
 
 
 
 
 
     US
 
 
1,212

 
889

 
36.3

36.3

—

     Intl
 
 
487

 
421

 
15.7

19.5

(3.8
)
     WW
 
 
1,698

 
1,310

 
29.6

30.9

(1.3
)
     TREMFYA
 
 
 
 
 
 
 
 
 
     US
 
 
221

 
143

 
54.3

54.3

—

     Intl
 
 
69

 
28

 
*

*

*

     WW
 
 
290

 
171

 
69.0

70.3

(1.3
)
     OTHER IMMUNOLOGY (4)
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
2

 
2

 
(4.4
)
(3.0
)
(1.4
)
     WW
 
 
2

 
2

 
(4.4
)
(3.0
)
(1.4
)
 
 
 
 
 
 
 
 
 
 
INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
US
 
 
418

 
345

 
21.2

21.2

—

Intl
 
 
421

 
478

 
(12.0
)
(9.0
)
(3.0
)
WW
 
 
839

 
823

 
1.9

3.6

(1.7
)
     EDURANT / rilpivirine
 
 
 
 
 
 
 
 
 
     US
 
 
12

 
13

 
(7.3
)
(7.3
)
—

     Intl
 
 
206

 
189

 
9.0

13.4

(4.4
)
     WW
 
 
218

 
202

 
7.9

12.1

(4.2
)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
 
 
 
 
 
 
     US
 
 
373

 
297

 
25.4

25.4

—

     Intl
 
 
135

 
193

 
(29.8
)
(28.1
)
(1.7
)
     WW
 
 
508

 
490

 
3.7

4.4

(0.7
)
     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
     US
 
 
33

 
35

 
(4.3
)
(4.3
)
—

     Intl
 
 
80

 
96

 
(17.4
)
(14.9
)
(2.5
)
     WW
 
 
113

 
131

 
(13.9
)
(12.1
)
(1.8
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
THIRD QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEUROSCIENCE
 
 
 
 
 
 
 
 
 
US
 
$
785

 
651

 
20.7
 %
20.7
 %
—
 %
Intl
 
 
810

 
839

 
(3.5
)
(1.4
)
(2.1
)
WW
 
 
1,595

 
1,490

 
7.1

8.2

(1.1
)
     CONCERTA / methylphenidate
 
 
 
 
 
 
 
 
 
     US
 
 
84

 
57

 
48.2

48.2

—

     Intl
 
 
109

 
100

 
9.4

10.6

(1.2
)
     WW
 
 
193

 
157

 
23.5

24.3

(0.8
)
     INVEGA SUSTENNA / XEPLION / INVEGA
 
 
 
 
 
     TRINZA / TREVICTA
 
 
 
 
 
 
 
 
 
     US
 
 
554

 
468

 
18.3

18.3

—

     Intl
 
 
297

 
281

 
5.9

9.4

(3.5
)
     WW
 
 
851

 
749

 
13.7

15.0

(1.3
)
     RISPERDAL CONSTA
 
 
 
 
 
 
 
 
 
     US
 
 
79

 
76

 
4.9

4.9

—

     Intl
 
 
89

 
99

 
(10.5
)
(7.5
)
(3.0
)
     WW
 
 
167

 
175

 
(3.8
)
(2.2
)
(1.6
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
     US
 
 
68

 
50

 
35.3

35.3

—

     Intl
 
 
316

 
359

 
(12.5
)
(11.5
)
(1.0
)
     WW
 
 
384

 
409

 
(6.6
)
(5.8
)
(0.8
)
 
 
 
 
 
 
 
 
 
 
ONCOLOGY
 
 
 
 
 
 
 
 
 
US
 
 
1,171

 
1,250

 
(6.3
)
(6.3
)
—

Intl
 
 
1,590

 
1,338

 
18.8

22.9

(4.1
)
WW
 
 
2,761

 
2,588

 
6.7

8.8

(2.1
)
     DARZALEX
 
 
 
 
 
 
 
 
 
     US
 
 
402

 
318

 
26.1

26.1

—

     Intl
 
 
363

 
180

 
*

*

*

     WW
 
 
765

 
498

 
53.5

56.6

(3.1
)
     IMBRUVICA
 
 
 
 
 
 
 
 
 
     US
 
 
447

 
334

 
34.0

34.0

—

     Intl
 
 
475

 
371

 
27.6

33.0

(5.4
)
     WW
 
 
921

 
705

 
30.6

33.5

(2.9
)
     VELCADE
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
149

 
271

 
(44.8
)
(44.4
)
(0.4
)
     WW
 
 
149

 
271

 
(44.8
)
(44.4
)
(0.4
)
     ZYTIGA / abiraterone acetate
 
 
 
 
 
 
 
 
 
     US
 
 
233

 
527

 
(55.8
)
(55.8
)
—

     Intl
 
 
508

 
431

 
17.8

21.1

(3.3
)
     WW
 
 
741

 
958

 
(22.7
)
(21.2
)
(1.5
)
     OTHER ONCOLOGY
 
 
 
 
 
 
 
 
 
     US
 
 
91

 
71

 
26.7

26.7

—

     Intl
 
 
95

 
85

 
12.2

16.7

(4.5
)
     WW
 
 
186

 
156

 
18.8

21.3

(2.5
)
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
THIRD QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
PULMONARY HYPERTENSION
 
 
 
 
 
 
US
 
$
427

 
425

 
0.5
 %
0.5
 %
—
 %
Intl
 
 
227

 
231

 
(1.6
)
0.6

(2.2
)
WW
 
 
654

 
656

 
(0.3
)
0.5

(0.8
)
     OPSUMIT
 
 
 
 
 
 
 
 
 
     US
 
 
206

 
182

 
12.9

12.9

—

     Intl
 
 
140

 
128

 
10.1

13.2

(3.1
)
     WW
 
 
347

 
310

 
11.7

13.0

(1.3
)
     TRACLEER / bosentan
 
 
 
 
 
 
 
 
 
     US
 
 
19

 
69

 
(72.4
)
(72.4
)
—

     Intl
 
 
46

 
70

 
(32.8
)
(33.5
)
0.7

     WW
 
 
65

 
139

 
(52.7
)
(53.0
)
0.3

     UPTRAVI
 
 
 
 
 
 
 
 
 
     US
 
 
185

 
154

 
20.2

20.2

—

     Intl
 
 
25

 
17

 
52.1

58.7

(6.6
)
     WW
 
 
210

 
171

 
23.4

24.0

(0.6
)
     OTHER
 
 
 
 
 
 
 
     US
 
 
17

 
20

 
(10.1
)
(10.1
)
—

     Intl
 
 
15

 
16

 
(15.4
)
(11.6
)
(3.8
)
     WW
 
 
31

 
36

 
(12.6
)
(10.8
)
(1.8
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
THIRD QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
CARDIOVASCULAR / METABOLISM / OTHER
 
 
 
 
 
 
US
 
$
955

 
1,026

 
(6.9
)%
(6.9
)%
—
 %
Intl
 
 
360

 
365

 
(1.3
)
1.1

(2.4
)
WW
 
 
1,316

 
1,391

 
(5.4
)
(4.8
)
(0.6
)
     XARELTO
 
 
 
 
 
 
 
 
 
     US
 
 
613

 
612

 
0.1

0.1

—

     Intl
 
 
—

 
—

 
—

—

—

     WW
 
 
613

 
612

 
0.1

0.1

—

     INVOKANA / INVOKAMET
 
 
 
 
 
 
 
 
 
     US
 
 
125

 
150

 
(16.6
)
(16.6
)
—

     Intl
 
 
55

 
40

 
33.9

37.8

(3.9
)
     WW
 
 
179

 
190

 
(5.8
)
(5.0
)
(0.8
)
     PROCRIT / EPREX
 
 
 
 
 
 
 
 
 
     US
 
 
126

 
178

 
(29.6
)
(29.6
)
—

     Intl
 
 
72

 
77

 
(5.7
)
(4.4
)
(1.3
)
     WW
 
 
198

 
255

 
(22.4
)
(22.0
)
(0.4
)
     OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
91

 
86

 
8.1

8.1

—

     Intl
 
 
234

 
248

 
(5.7
)
(3.2
)
(2.5
)
     WW
 
 
325

 
334

 
(2.2
)
(0.3
)
(1.9
)
 
 
 
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
US
 
 
6,340

 
6,097

 
4.0

4.0

—

Intl
 
 
4,537

 
4,249

 
6.8

10.0

(3.2
)
WW
 
$
10,877

 
10,346

 
5.1
 %
6.4
 %
(1.3
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
THIRD QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

MEDICAL DEVICES SEGMENT (2) (5)
 
 
 
 
 
 
 
 
 
 
 
 
 
DIABETES CARE (5)
 
 
 
 
 
 
US
 
$
—

 
125

 
*%

*%

—
 %
Intl
 
 
—

 
190

 
*

*

*

WW
 
 
—

 
315

 
*

*

*

 
 
 
 
 
 
 
 
 
 
INTERVENTIONAL SOLUTIONS
 
 
 
 
 
 
 
 
 
US
 
 
357

 
320

 
11.5

11.5

—

Intl
 
 
382

 
333

 
15.3

17.0

(1.7
)
WW
 
 
741

 
653

 
13.4

14.3

(0.9
)
 
 
 
 
 
 
 
 
 
 
ORTHOPAEDICS
 
 
 
 
 
 
 
 
 
US
 
 
1,301

 
1,284

 
1.2

1.2

—

Intl
 
 
837

 
827

 
1.2

4.1

(2.9
)
WW
 
 
2,138

 
2,111

 
1.2

2.3

(1.1
)
 
 
 
 
 
 
 
 
 
 
     HIPS
 
 
 
 
 
 
 
 
 
     US
 
 
204

 
201

 
1.1

1.1

—

     Intl
 
 
133

 
129

 
2.7

5.7

(3.0
)
     WW
 
 
336

 
330

 
1.7

2.9

(1.2
)
 
 
 
 
 
 
 
 
 
 
     KNEES
 
 
 
 
     US
 
 
209

 
215

 
(2.7
)
(2.7
)
—

     Intl
 
 
136

 
126

 
7.9

10.8

(2.9
)
     WW
 
 
344

 
341

 
1.2

2.3

(1.1
)
 
 
 
 
 
 
 
 
 
 
     TRAUMA
 
 
 
 
 
 
 
 
 
     US
 
 
415

 
395

 
5.1

5.1

—

     Intl
 
 
262

 
259

 
1.0

4.2

(3.2
)
     WW
 
 
677

 
654

 
3.5

4.7

(1.2
)
 
 
 
 
 
 
 
 
 
 
     SPINE & OTHER
 
 
     US
 
 
472

 
473

 
(0.2
)
(0.2
)
—

     Intl
 
 
306

 
313

 
(2.0
)
0.6

(2.6
)
     WW
 
 
778

 
786

 
(0.9
)
0.1

(1.0
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 


Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
THIRD QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

MEDICAL DEVICES SEGMENT (2) (5) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
SURGERY
 
 
 
 
 
 
US
 
$
940

 
1,016

 
(7.4
)%
(7.4
)%
—
 %
Intl
 
 
1,371

 
1,360

 
0.8

3.5

(2.7
)
WW
 
 
2,311

 
2,376

 
(2.7
)
(1.2
)
(1.5
)
 
 
 
 
 
 
 
 
 
 
     ADVANCED
 
 
 
 
 
 
 
 
 
     US
 
 
409

 
421

 
(2.8
)
(2.8
)
—

     Intl
 
 
602

 
555

 
8.3

11.2

(2.9
)
     WW
 
 
1,010

 
976

 
3.6

5.2

(1.6
)
 
 
 
 
 
 
 
 
 
 
     GENERAL
 
 
 
 
 
 
 
 
 
     US
 
 
443

 
423

 
4.7

4.7

—

     Intl
 
 
659

 
657

 
0.2

2.9

(2.7
)
     WW
 
 
1,101

 
1,080

 
1.9

3.6

(1.7
)
 
 
 
 
 
 
 
 
 
 
     SPECIALTY
 
 
 
 
 
 
 
 
 
     US
 
 
88

 
172

 
(48.0
)
(48.0
)
—

     Intl
 
 
110

 
148

 
(25.0
)
(23.1
)
(1.9
)
     WW
 
 
200

 
320

 
(37.4
)
(36.5
)
(0.9
)
 
 
 
 
 
 
 
 
 
 
VISION
 
 
 
 
US
 
 
459

 
452

 
1.4

1.4

—

Intl
 
 
734

 
680

 
8.0

9.1

(1.1
)
WW
 
 
1,193

 
1,132

 
5.4

6.1

(0.7
)
 
 
 
 
 
 
 
 
 
 
     CONTACT LENSES / OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
339

 
319

 
6.2

6.2

—

     Intl
 
 
555

 
516

 
7.4

8.4

(1.0
)
     WW
 
 
893

 
835

 
7.0

7.6

(0.6
)
     SURGICAL
 
 
 
 
 
 
 
 
 
     US
 
 
120

 
133

 
(10.0
)
(10.0
)
—

     Intl
 
 
180

 
164

 
9.9

11.3

(1.4
)
     WW
 
 
299

 
297

 
0.9

1.7

(0.8
)
 
 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
US
 
 
3,057

 
3,197

 
(4.4
)
(4.4
)
—

Intl
 
 
3,326

 
3,390

 
(1.9
)
0.3

(2.2
)
WW
 
$
6,383

 
6,587

 
(3.1
)%
(2.0
)%
(1.1
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
NINE MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

CONSUMER SEGMENT (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BABY CARE
 
 
 
 
 
 
 
 
 
US
 
$
277

 
306

 
(9.5
)%
(9.5
)%
—
 %
Intl
 
 
977

 
1,079

 
(9.5
)
(3.7
)
(5.8
)
WW
 
 
1,254

 
1,385

 
(9.5
)
(5.0
)
(4.5
)
 
 
 
 
 
 
 
 
 
 
BEAUTY
 
 
 
 
 
 
 
 
 
US
 
 
1,810

 
1,791

 
1.1

1.1

—

Intl
 
 
1,633

 
1,480

 
10.4

15.3

(4.9
)
WW
 
 
3,443

 
3,271

 
5.3

7.5

(2.2
)
 
 
 
 
 
 
 
 
 
 
ORAL CARE
 
 
 
 
 
 
 
 
 
US
 
 
462

 
472

 
(2.1
)
(2.1
)
—

Intl
 
 
673

 
684

 
(1.7
)
3.7

(5.4
)
WW
 
 
1,135

 
1,156

 
(1.8
)
1.3

(3.1
)
 
 
 
 
 
 
 
 
 
 
OTC
 
 
 
 
 
 
 
 
 
US
 
 
1,468

 
1,359

 
8.0

8.0

—

Intl
 
 
1,781

 
1,827

 
(2.5
)
2.7

(5.2
)
WW
 
 
3,249

 
3,186

 
2.0

5.0

(3.0
)
 
 
 
 
 
 
 
 
 
 
WOMEN'S HEALTH
 
 
 
 
 
 
 
 
 
US
 
 
9

 
10

 
(3.8
)
(3.8
)
—

Intl
 
 
724

 
782

 
(7.5
)
0.4

(7.9
)
WW
 
 
733

 
792

 
(7.4
)
0.4

(7.8
)
 
 
 
 
 
 
 
 
 
 
WOUND CARE / OTHER
 
 
 
 
 
 
 
 
 
US
 
 
343

 
344

 
(0.4
)
(0.4
)
—

Intl
 
 
173

 
183

 
(5.0
)
(1.1
)
(3.9
)
WW
 
 
516

 
527

 
(2.0
)
(0.7
)
(1.3
)
 
 
 
 
 
 
 
 
 
 
TOTAL CONSUMER
 
 
 
 
 
 
 
 
 
US
 
 
4,369

 
4,282

 
2.0

2.0

—

Intl
 
 
5,962

 
6,035

 
(1.2
)
4.3

(5.5
)
WW
 
$
10,331

 
10,317

 
0.1
 %
3.4
 %
(3.3
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 





Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
NINE MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (4)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMMUNOLOGY
 
 
 
 
 
 
 
 
 
US
 
$
7,124

 
6,717

 
6.1
 %
6.1
 %
—
 %
Intl
 
 
3,304

 
3,061

 
8.0

13.9

(5.9
)
WW
 
 
10,428

 
9,778

 
6.7

8.5

(1.8
)
     REMICADE
 
 
 
 
 
 
 
 
 
     US
 
 
2,324

 
2,821

 
(17.6
)
(17.6
)
—

     US Exports (3)
 
 
226

 
346

 
(34.7
)
(34.7
)
—

     Intl
 
 
795

 
921

 
(13.7
)
(8.6
)
(5.1
)
     WW
 
 
3,345

 
4,088

 
(18.2
)
(17.0
)
(1.2
)
     SIMPONI / SIMPONI ARIA
 
 
 
 
 
 
 
 
 
     US
 
 
857

 
779

 
10.0

10.0

—

     Intl
 
 
816

 
823

 
(0.8
)
4.6

(5.4
)
     WW
 
 
1,673

 
1,602

 
4.5

7.2

(2.7
)
     STELARA
 
 
 
 
 
 
 
 
 
     US
 
 
3,152

 
2,460

 
28.1

28.1

—

     Intl
 
 
1,509

 
1,252

 
20.5

27.1

(6.6
)
     WW
 
 
4,661

 
3,712

 
25.6

27.8

(2.2
)
     TREMFYA
 
 
 
 
 
 
 
 
 
     US
 
 
565

 
311

 
81.7

81.7

—

     Intl
 
 
177

 
58

 
*

*

*

     WW
 
 
742

 
369

 
*

*

*

     OTHER IMMUNOLOGY (4)
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
8

 
7

 
13.7

14.4

(0.7
)
     WW
 
 
8

 
7

 
13.7

14.4

(0.7
)
 
 
 
 
 
 
 
 
 
 
INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
US
 
 
1,162

 
1,006

 
15.5

15.5

—

Intl
 
 
1,385

 
1,496

 
(7.4
)
(1.2
)
(6.2
)
WW
 
 
2,547

 
2,502

 
1.8

5.5

(3.7
)
     EDURANT / rilpivirine
 
 
 
 
 
 
 
 
 
     US
 
 
36

 
42

 
(14.3
)
(14.3
)
—

     Intl
 
 
603

 
581

 
3.8

10.1

(6.3
)
     WW
 
 
639

 
623

 
2.6

8.5

(5.9
)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
 
 
 
 
 
 
     US
 
 
1,032

 
847

 
21.8

21.8

—

     Intl
 
 
534

 
613

 
(12.8
)
(6.5
)
(6.3
)
     WW
 
 
1,566

 
1,460

 
7.3

9.9

(2.6
)
     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
     US
 
 
94

 
117

 
(19.6
)
(19.6
)
—

     Intl
 
 
248

 
302

 
(18.2
)
(12.1
)
(6.1
)
     WW
 
 
342

 
419

 
(18.6
)
(14.2
)
(4.4
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
NINE MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEUROSCIENCE
 
 
 
 
 
 
 
 
 
US
 
$
2,172

 
1,914

 
13.5
 %
13.5
 %
—
 %
Intl
 
 
2,590

 
2,663

 
(2.7
)
2.4

(5.1
)
WW
 
 
4,762

 
4,577

 
4.0

7.0

(3.0
)
     CONCERTA / methylphenidate
 
 
 
 
 
 
 
 
 
     US
 
 
196

 
191

 
2.9

2.9

—

     Intl
 
 
348

 
322

 
8.0

12.9

(4.9
)
     WW
 
 
544

 
513

 
6.1

9.2

(3.1
)
     INVEGA SUSTENNA / XEPLION / INVEGA
 
 
 
 
 
     TRINZA / TREVICTA
 
 
 
 
 
 
 
 
 
     US
 
 
1,543

 
1,306

 
18.1

18.1

—

     Intl
 
 
916

 
859

 
6.7

13.0

(6.3
)
     WW
 
 
2,459

 
2,165

 
13.6

16.1

(2.5
)
     RISPERDAL CONSTA
 
 
 
 
 
 
 
 
 
     US
 
 
237

 
238

 
(0.5
)
(0.5
)
—

     Intl
 
 
292

 
321

 
(9.1
)
(3.2
)
(5.9
)
     WW
 
 
528

 
559

 
(5.4
)
(2.1
)
(3.3
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
     US
 
 
196

 
179

 
9.7

9.7

—

     Intl
 
 
1,035

 
1,161

 
(10.9
)
(6.8
)
(4.1
)
     WW
 
 
1,231

 
1,340

 
(8.2
)
(4.6
)
(3.6
)
 
 
 
 
 
 
 
 
 
 
ONCOLOGY
 
 
 
 
 
 
 
 
 
US
 
 
3,146

 
3,268

 
(3.7
)
(3.7
)
—

Intl
 
 
4,830

 
4,087

 
18.2

25.2

(7.0
)
WW
 
 
7,976

 
7,355

 
8.4

12.3

(3.9
)
     DARZALEX
 
 
 
 
 
 
 
 
 
     US
 
 
1,123

 
880

 
27.6

27.6

—

     Intl
 
 
1,045

 
561

 
86.2

98.7

(12.5
)
     WW
 
 
2,168

 
1,441

 
50.4

55.3

(4.9
)
     IMBRUVICA
 
 
 
 
 
 
 
 
 
     US
 
 
1,163

 
811

 
43.5

43.5

—

     Intl
 
 
1,373

 
1,101

 
24.6

33.0

(8.4
)
     WW
 
 
2,536

 
1,912

 
32.6

37.4

(4.8
)
     VELCADE
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
636

 
864

 
(26.3
)
(22.8
)
(3.5
)
     WW
 
 
636

 
864

 
(26.3
)
(22.8
)
(3.5
)
     ZYTIGA / abiraterone acetate
 
 
 
 
 
 
 
 
 
     US
 
 
616

 
1,420

 
(56.6
)
(56.6
)
—

     Intl
 
 
1,502

 
1,292

 
16.2

22.1

(5.9
)
     WW
 
 
2,118

 
2,712

 
(21.9
)
(19.1
)
(2.8
)
     OTHER ONCOLOGY
 
 
 
 
 
 
 
 
 
     US
 
 
245

 
157

 
54.7

54.7

—

     Intl
 
 
274

 
269

 
2.1

8.9

(6.8
)
     WW
 
 
519

 
426

 
21.6

25.9

(4.3
)
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
NINE MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
PULMONARY HYPERTENSION
 
 
 
 
 
 
US
 
$
1,296

 
1,215

 
6.6
 %
6.6
 %
—
 %
Intl
 
 
704

 
691

 
1.9

7.3

(5.4
)
WW
 
 
2,000

 
1,906

 
4.9

6.9

(2.0
)
     OPSUMIT
 
 
 
 
 
 
 
 
 
     US
 
 
581

 
511

 
13.7

13.7

—

     Intl
 
 
419

 
381

 
10.2

16.4

(6.2
)
     WW
 
 
1,001

 
892

 
12.2

14.9

(2.7
)
     TRACLEER / bosentan
 
 
 
 
 
 
 
 
 
     US
 
 
121

 
208

 
(41.8
)
(41.8
)
—

     Intl
 
 
164

 
214

 
(23.3
)
(20.8
)
(2.5
)
     WW
 
 
285

 
422

 
(32.4
)
(31.1
)
(1.3
)
     UPTRAVI
 
 
 
 
 
 
 
 
 
     US
 
 
536

 
433

 
23.9

23.9

—

     Intl
 
 
75

 
49

 
52.8

61.5

(8.7
)
     WW
 
 
611

 
482

 
26.8

27.7

(0.9
)
     OTHER
 
 
 
 
 
 
 
     US
 
 
58

 
63

 
(8.9
)
(8.9
)
—

     Intl
 
 
46

 
47

 
(3.0
)
5.4

(8.4
)
     WW
 
 
103

 
110

 
(6.4
)
(2.9
)
(3.5
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
NINE MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
CARDIOVASCULAR / METABOLISM / OTHER
 
 
 
 
 
 
US
 
$
2,804

 
3,230

 
(13.2
)%
(13.2
)%
—
 %
Intl
 
 
1,131

 
1,196

 
(5.4
)
(0.7
)
(4.7
)
WW
 
 
3,936

 
4,426

 
(11.1
)
(9.8
)
(1.3
)
     XARELTO
 
 
 
 
 
 
 
 
 
     US
 
 
1,704

 
1,869

 
(8.9
)
(8.9
)
—

     Intl
 
 
—

 
—

 
—

—

—

     WW
 
 
1,704

 
1,869

 
(8.9
)
(8.9
)
—

     INVOKANA / INVOKAMET
 
 
 
 
 
 
 
 
 
     US
 
 
411

 
523

 
(21.3
)
(21.3
)
—

     Intl
 
 
147

 
130

 
12.3

17.9

(5.6
)
     WW
 
 
558

 
653

 
(14.6
)
(13.4
)
(1.2
)
     PROCRIT / EPREX
 
 
 
 
 
 
 
 
 
     US
 
 
387

 
523

 
(26.1
)
(26.1
)
—

     Intl
 
 
220

 
244

 
(9.8
)
(6.4
)
(3.4
)
     WW
 
 
607

 
767

 
(20.9
)
(19.8
)
(1.1
)
     OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
302

 
315

 
(3.8
)
(3.8
)
—

     Intl
 
 
765

 
822

 
(6.9
)
(2.0
)
(4.9
)
     WW
 
 
1,067

 
1,137

 
(6.1
)
(2.5
)
(3.6
)
 
 
 
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
US
 
 
17,705

 
17,350

 
2.0

2.0

—

Intl
 
 
13,945

 
13,194

 
5.7

11.7

(6.0
)
WW
 
$
31,650

 
30,544

 
3.6
 %
6.2
 %
(2.6
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
NINE MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

MEDICAL DEVICES SEGMENT (2) (5)
 
 
 
 
 
 
 
 
 
 
 
 
 
DIABETES CARE (5)
 
 
 
 
 
 
US
 
$
—

 
371

 
 *%

 *%

—
 %
Intl
 
 
—

 
638

 
*

*

*

WW
 
 
—

 
1,009

 
*

*

*

 
 
 
 
 
 
 
 
 
 
INTERVENTIONAL SOLUTIONS
 
 
 
 
 
 
 
 
 
US
 
 
1,066

 
947

 
12.6

12.6

—

Intl
 
 
1,156

 
1,013

 
14.2

19.0

(4.8
)
WW
 
 
2,223

 
1,960

 
13.4

15.9

(2.5
)
 
 
 
 
 
 
 
 
 
 
ORTHOPAEDICS
 
 
 
 
 
 
 
 
 
US
 
 
3,950

 
3,923

 
0.7

0.7

—

Intl
 
 
2,616

 
2,700

 
(3.1
)
2.0

(5.1
)
WW
 
 
6,566

 
6,623

 
(0.9
)
1.2

(2.1
)
 
 
 
 
 
 
 
 
 
 
     HIPS
 
 
 
 
 
 
 
 
 
     US
 
 
633

 
621

 
1.8

1.8

—

     Intl
 
 
428

 
432

 
(0.8
)
4.7

(5.5
)
     WW
 
 
1,061

 
1,053

 
0.7

3.0

(2.3
)
 
 
 
 
 
 
 
 
 
 
     KNEES
 
 
 
 
     US
 
 
650

 
672

 
(3.3
)
(3.3
)
—

     Intl
 
 
435

 
438

 
(0.6
)
4.4

(5.0
)
     WW
 
 
1,085

 
1,110

 
(2.2
)
(0.2
)
(2.0
)
 
 
 
 
 
 
 
 
 
 
     TRAUMA
 
 
 
 
 
 
 
 
 
     US
 
 
1,239

 
1,196

 
3.6

3.6

—

     Intl
 
 
795

 
829

 
(4.1
)
1.0

(5.1
)
     WW
 
 
2,034

 
2,025

 
0.4

2.5

(2.1
)
 
 
 
 
 
 
 
 
 
 
     SPINE & OTHER
 
 
     US
 
 
1,427

 
1,434

 
(0.5
)
(0.5
)
—

     Intl
 
 
957

 
1,001

 
(4.4
)
0.6

(5.0
)
     WW
 
 
2,384

 
2,435

 
(2.1
)
0.0

(2.1
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 


Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
NINE MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

MEDICAL DEVICES SEGMENT (2) (5) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
SURGERY
 
 
 
 
 
 
US
 
$
2,867

 
3,031

 
(5.4
)%
(5.4
)%
—
 %
Intl
 
 
4,192

 
4,283

 
(2.1
)
3.2

(5.3
)
WW
 
 
7,059

 
7,314

 
(3.5
)
(0.4
)
(3.1
)
 
 
 
 
 
 
 
 
 
 
     ADVANCED
 
 
 
 
 
 
 
 
 
     US
 
 
1,209

 
1,216

 
(0.6
)
(0.6
)
—

     Intl
 
 
1,811

 
1,731

 
4.6

10.1

(5.5
)
     WW
 
 
3,019

 
2,947

 
2.4

5.7

(3.3
)
 
 
 
 
 
 
 
 
 
 
     GENERAL
 
 
 
 
 
 
 
 
 
     US
 
 
1,311

 
1,282

 
2.3

2.3

—

     Intl
 
 
1,998

 
2,094

 
(4.6
)
0.6

(5.2
)
     WW
 
 
3,309

 
3,376

 
(2.0
)
1.2

(3.2
)
 
 
 
 
 
 
 
 
 
 
     SPECIALTY
 
 
 
 
 
 
 
 
 
     US
 
 
347

 
533

 
(34.9
)
(34.9
)
—

     Intl
 
 
383

 
458

 
(16.2
)
(11.1
)
(5.1
)
     WW
 
 
731

 
991

 
(26.2
)
(23.9
)
(2.3
)
 
 
 
 
 
 
 
 
 
 
VISION
 
 
 
 
US
 
 
1,366

 
1,351

 
1.1

1.1

—

Intl
 
 
2,117

 
2,069

 
2.3

6.1

(3.8
)
WW
 
 
3,483

 
3,420

 
1.8

4.1

(2.3
)
 
 
 
 
 
 
 
 
 
 
     CONTACT LENSES / OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
993

 
948

 
4.7

4.7

—

     Intl
 
 
1,566

 
1,538

 
1.8

5.7

(3.9
)
     WW
 
 
2,559

 
2,486

 
2.9

5.4

(2.5
)
     SURGICAL
 
 
 
 
 
 
 
 
 
     US
 
 
373

 
403

 
(7.4
)
(7.4
)
—

     Intl
 
 
551

 
531

 
3.7

7.3

(3.6
)
     WW
 
 
923

 
934

 
(1.1
)
0.9

(2.0
)
 
 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
US
 
 
9,249

 
9,623

 
(3.9
)
(3.9
)
—

Intl
 
 
10,082

 
10,703

 
(5.8
)
(1.0
)
(4.8
)
WW
 
$
19,331

 
20,326

 
(4.9
)%
(2.4
)%
(2.5
)%
 
 
 
 
 
 
 
 
 
 
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
 
 
 
 
 
 
 
 
 
 
* Percentage greater than 100% or not meaningful
 
 
 
 
(1) Operational growth excludes the effect of translational currency
 
 
(2) Unaudited
 
 
 
 
 
 
 
 
 
(3) Reported as U.S. sales
 
 
 
 
 
 
 
 
 
(4) Prior year amounts have been reclassified to conform to current year product disclosure
(5) Reflects LifeScan divestiture October 2, 2018